Pathology and diagnosis of nephroblastoma
Dr Gordan Vujanic – University of Cardiff, UK
Pathology and diagnosis of nephroblastoma ( Dr Gordan Vujanic – University of Cardiff, UK )
27 Nov 2013
Engineering of polymeric nanoparticles for medical applications
Dr Omid Farokhzad - Harvard Medical School, Boston, USA
Engineering of polymeric nanoparticles for medical applications ( Dr Omid Farokhzad - Harvard Medical School, Boston, USA )
14 Nov 2013
Molecular imaging using PET-CT and personalised therapy with neuroendocrine tumo...
Dr Harshad Kulkarni - Zentralklinik, Bad Berka, Germany
Molecular imaging using PET-CT and personalised therapy with neuroendocrine tumours ( Dr Harshad Kulkarni - Zentralklinik, Bad Berka, Germany )
12 Nov 2013
The immune microenvironment as an anti-cancer therapeutic strategy
Dr Lisa Coussens - Oregon Science & Health University, USA
The immune microenvironment as an anti-cancer therapeutic strategy ( Dr Lisa Coussens - Oregon Science & Health University, USA )
12 Nov 2013
SBRT in tumours of the spinal column
Dr Peter Gerszten - University of Pittsburgh, USA
SBRT in tumours of the spinal column ( Dr Peter Gerszten - University of Pittsburgh, USA )
15 Aug 2013
Editor’s Choice - ecancermedicalscience August 2013
Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
Editor’s Choice - ecancermedicalscience August 2013 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
8 Aug 2013
ECC 2013 Preview: Scientific programme highlights
Prof Vincenzo Valentini and Ian Banks
ECC 2013 Preview: Scientific programme highlights ( Prof Vincenzo Valentini and Ian Banks )
11 Jul 2013
Adding bevacizumab to standard first-line chemoradiation for glioblastoma gives ...
Prof Mark Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA
Adding bevacizumab to standard first-line chemoradiation for glioblastoma gives no survival benefit ( Prof Mark Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA )
6 Jun 2013
Science behind phase I clinical trials: targeting tumour cell development pathwa...
Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA
Science behind phase I clinical trials: targeting tumour cell development pathways ( Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA )
6 Jun 2013
No survival benefit to adding bevacizumab to standard first-line chemoradiation ...
Dr Mark R. Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA
No survival benefit to adding bevacizumab to standard first-line chemoradiation for glioblastoma ( Dr Mark R. Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA )
2 Jun 2013
Improving outcomes of childhood neuroblastoma
Dr Garrett Brodeur - Cancer Center at The Children’s Hospital of Philadelphia, U...
Improving outcomes of childhood neuroblastoma ( Dr Garrett Brodeur - Cancer Center at The Children’s Hospital of Philadelphia, USA )
1 Jun 2013
Profiles of malignant GCTs and potential biomarkers for CNS germ cell tumours
Dr Matthew Murray - Cambridge Cancer Centre, UK
Profiles of malignant GCTs and potential biomarkers for CNS germ cell tumours ( Dr Matthew Murray - Cambridge Cancer Centre, UK )
29 May 2013